A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs ASG 15ME (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Agensys; Astellas Pharma
- 11 Nov 2019 Status changed from active, no longer recruiting to completed.
- 25 Feb 2019 Planned End Date changed from 1 Mar 2019 to 1 Jan 2020.
- 25 Feb 2019 Planned primary completion date changed from 1 Mar 2019 to 1 Jan 2020.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History